PACB — Pacific Biosciences Of California Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Market Cap
$327.05m
Enterprise Value
$584.61m
Revenue
$154.01m

Annual income statement for Pacific Biosciences Of California, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	78.9	131	128	201	154
Cost of Revenue
Gross Profit	32.6	58.9	52.7	56.2	38.3
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	51.3	393	436	537	474
Operating Profit	27.6	-262	-307	-337	-320
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	29.4	-275	-314	-318	-310
Provision for Income Taxes
Net Income After Taxes	29.4	-181	-314	-307	-310
Net Income Before Extraordinary Items
Net Income	29.4	-181	-314	-307	-310
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	29.4	-181	-314	-307	-310
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.586	-0.623	-1.38	-1.17	-0.996